In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic's heart device monitor:

This article was originally published in Clinica

Executive Summary

Medtronic has obtained approval to CE mark the automatic version of its internet-based monitoring system, CareLink, in the EU. The Minnesota, Minneapolis-based company immediately launched the product onto the European market. The CareLink Network employs Conexus wireless telemetry to automatically transmit data on patients with implanted heart devices, and on the devices themselves, directly to physicians. It can be used to assess the performance of devices such as cardiac resynchronisation therapy-defibrillators (CRT-D) for patients with heart failure and implantable cardioverter defibrillators (ICDs) for patients with arrhythmia. The network can also monitor fluid build-up in the thoracic cavity (a precursor to heart failure) via a proprietary feature called OptiVol Fluid Status Monitoring. Medtronic claims that a non-wireless version of the system is used by 150,000 patients with heart failure or arrhythmia worldwide.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts